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Abstract
Background: The treatment of cardiogenic shock with percutaneous mechanical circulatory support (MCS)
is attractive: however, at present it is not clear which is the best strategy, as no survival benefit has been
demonstrated for any device as single therapy. Aim of this study is to describe the role of percutaneous
Impella in a comprehensive MCS program.
Methods: Observational study on 22 patients supported with the Impella device in our hospital from May
2013 to June 2014.
Results: Four patients (18 %) were treated with Impella alone, 8 patients (36 %) were treated with Impella and IABP,
6 patients (27 %) with Impella and VA ECMO, and 4 patients (18 %) with Impella, IABP and VA ECMO.
The cause of cardiogenic shock was myocardial infarction (CSMI) in 9 patients (41 %), postcardiotomic
cardiogenic shock in 5 (23 %), and a miscellaneous of other causes in the remaining 8 (36 %). Eight Impella
devices (36 %) were placed under transesophageal echocardiographic guidance, while 14 (64 %) under
fluoroscopy. The device was removed with manual compression at bedside and no vascular complications
were observed.
Duration of Impella support was 107 (54–141) hours and duration of ventilation was 48 (14–92) hours.
Hemolysis occurred in 6 patients (27 %), while major bleeding in 4 patients (18 %). Survival was 73 %: 13
patients (58 %) showed recovery of cardiac function; 1 patient (5 %) was bridged to left ventricular assist device
(LVAD) implantation, 1 patient (5 %) to heart transplantation (HTx) and 1 patient (5 %) received a BiVAD and
was eventually bridged to HTx.
Conclusions: Our data suggest that a multi-device approach, encompassing active LV support with Impella, is
safe and can significantly improve survival in patients with cardiogenic shock.
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Background
Mechanical circulatory support (MCS) is considered the
standard of care in the treatment of refractory cardiogenic
shock (CS). The availability of temporary left and biventri-
cular assist devices, placed either percutaneously or surgi-
cally, has widened the therapeutic armamentarium beyond
the use of intraaortic balloon pump counterpulsation
(IABP) and venoarterial extracorporeal membrane oxygen-
ation (VA ECMO).
In this context, the Impella device (ABIOMED Inc, Dan-
vers, MA) has gained extraordinary diffusion, because it is
safe, easy to use and its efficacy has been proven in many
clinical scenarios [1–5].
Impella technology comprises Impella 2.5, the Impella
CP, and Impella 5.0/LD devices, which can generate up to
2.5 L/min, 4 L/min, and 5.0 L/min of forward flow in the
systemic circulation, respectively [6, 7]. Although strong
evidence exists regarding the efficacy of MCS devices in the
treatment of cardiogenic shock, a combined multidevice
approach is not commonly reported.
The CS patient population suffering from refractory
cardiogenic shock is extremely heterogeneous in terms
of etiology of CS (e.g., myocardial infarction, postcardio-
tomic shock, out-of hospital cardiac arrest, myocarditis)
and careful tailoring of therapeutic options is mandatory.
The concomitant use of different devices may overcome
the limitations of each form of support.
Although the treatment of cardiogenic shock with MCS
plays a crucial role in clinical practice, the best strategy is
still uncertain, as no survival benefit has been demonstrated
for any device as the sole therapy so far [8]. Aim of this
study is to describe the role of percutaneous Impella device
in the contemporary MCS armamentarium.
Methods
The present study is in compliance with the Helsinki Dec-
laration. After approval by the local ethical committee
(“Ospedale San Raffaele Ethical Committee”), we
performed a prospective observational study of all the pa-
tients treated with Impella devices in the Cardiac Intensive
Care Unit of IRCCS San Raffaele Scientific Institute from
May 2013 to June 2014. The patients in our Department
signed a written consent for the use of their data for scien-
tific purpose. No specific written consent was obtained
since all patients’ data were anonymized and de-identified
prior to analysis.
All patients received either the 2.5 Impella device or CP
Impella device. The Impella device was inserted either
under fluoroscopy in the cath lab, or at bedside under
transesophageal (TE) echocardiographic guidance, accord-
ing to the clinical situation. The Impella pump speed was
set to optimally unload the LV as assessed with transesoph-
ageal echocardiography.
Removal of the Impella device was performed percutan-
eously, with manual compression of the access site for at
least 45 min. General baseline information, data on mech-
anical circulatory support and its duration, together with
the outcomes were recorded for all patients. Hemodynamic
and echocardiographic data were collected for the study
population at 5 time points: before Impella implantation,
30 min after implantation, 24 h after implantation, at wean-
ing (i.e. recorded in the 24 h before device removal), 24 h
after device discontinuation.
Some patients received concomitant mechanical circula-
tory support with IABP and/or VA ECMO. The ECMO cir-
cuit setup included a centrifugal pump and a coated
polymethylpentene oxygenator. In case of peripheral can-
nulation, outlet cannulas ranged from 21 to 29 French, and
inlet cannulas from 15 to 19 French. Patients undergoing
central VA ECMO cannulation had an outlet cannula of
32–34 French, and an inlet cannula of 20–24 Fr. A distal
perfusion cannula was placed whenever possible in all pa-
tients undergoing peripheral VA ECMO (range 5–8
French) to prevent leg ischemia. Patients who needed intra-
venous anticoagulation were administered bivalirudin ti-
trated to an activated partial thromboplastin time (aPTT)
between 45 and 60 s. In the absence of contraindications,
the purge fluid of Impella device also contained unfractio-
nated heparin (either 25U/ml or 50 U/ml) according to
clinical need. Hemolysis was defined as an increase in
serum LDH levels above 1000 U/l associated with an in-
crease in free plasma hemoglobin above the upper limit of
laboratory range in at least 2 consecutive blood samples
within 24 h. Major bleeding was defined as intracranial, in-
traocular, retropharyngeal or retroperitoneal bleeding re-
quiring either radiological intervention or surgical revision
or decrease in serum hemoglobin >3 g/dl or the need for
transfusion of at least two packed red blood cell units.
Inotropic score (IS) was calculated as: (dopamine μg/
kg/min × 1) + (dobutamine μg/kg/min × 1) + (milrinone
μg/kg/min × 15) + (epinephrine/norepinephrine μg/kg/
min x 100) [9]. Vascular complications included access
site or access-related vascular injury requiring un-
planned percutaneous or surgical intervention, and distal
embolization.
In the absence of a standardized definition, right ven-
tricular dysfunction was diagnosed if at least 2 out of the
following criteria were present at echocardiographic
evaluation: severe tricuspid valve regurgitation, end dia-
stolic right ventricular diameter ≥35 mm, a value of tri-
cuspid annular plane systolic excursion (TAPSE) <1.5
cm, a value of sTDI of tricuspid anulus <10 cm/sec and
poor ejection fraction.
Statistical analysis
Categorical variables are reported as numbers (percent-
ages), whereas continuous variables are expressed as
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mean ± standard deviation and median with interquar-
tile range (25th-75th percentile). The analysis of variance
(ANOVA) was used to estimate the time interaction for
each variable. Data were analyzed using Microsoft Excel
2007 (Microsoft Office 2007, Redmon, WA, US) and
SAS 9.2 (SAS Institute Inc. Cary, NC, USA).
Results
Twenty-two patients received mechanical circulatory
support with Impella during the study period. Baseline
characteristics of the patients are shown in Table 1.
Twenty patients (90 %) were male. Mean age was 60 ±
13 years. As shown in Table 2, the cause of cardiogenic
shock was myocardial infarction in 9 patients (41 %),
and postcardiotomic cardiogenic shock in 5 (23 %). Indi-
cation to Impella implantation, together with MCS-
related management and outcomes can be found in
Table 2. The outcomes of the whole population are fur-
ther presented in the Table 3. Nineteen patients (86 %)
were treated with Impella 2.5, while the 3 remaining
patients (14 %) received Impella CP.
Four patients (18 %) were treated with Impella alone,
while 18 patients underwent Impella support in the con-
text of a multidevice strategy: 8 patients (36 %) were
treated with Impella on top of IABP, 6 patients (27 %)
with Impella and VA ECMO (Impella was placed within
the first 24 h as active left ventricular venting), and 4 pa-
tients (18 %) with Impella, IABP, and VA ECMO.
Of these 4 patients, 3 had central VA ECMO and 1 per-
ipheral VA ECMO. Two patients had severe and 3 had
moderate aortic regurgitation at the time of Impella place-
ment. Eight Impella devices (36 %) were inserted at
bedside under TE echocardiography, while 14 (64 %) in
the catheterisation laboratory under fluoroscopic guid-
ance. Success rate of implantation was 100 % and no
device failure was observed. Device removal was per-
formed with manual compression at bedside; we do not
report any vascular complications. Median duration of
Impella support was 107 (54–141) hours.
Hemolysis was observed in 6 patients (27 %). Major
bleeding occurred in 4 patients (18 %): 2 cases of gastro-
intestinal bleeding and 2 cases of cardiac tamponade
after cardiac surgery. No patient who received isolated
Impella support experienced bleeding. None of the
bleedings could be attributed to the Impella device. We
do not report any episode of Impella-related vascular
complication. One episode (5 %) of Impella-related ven-
tricular arrhythmia was recorded. No neurological com-
plications was recorded. Sixteen patients (73 %) received
mechanical ventilation during support, while 6 patients
(27 %) were in spontaneous breathing during the whole
period of mechanical circulatory support. Median dur-
ation of mechanical ventilation was 48 (14–92) hours.
Four patients (18 %) suffered from acute renal failure re-
quiring continuous venovenous hemofiltration (CVVH),
and one patient with chronic liver insufficiency required
molecular adsorbent recirculation system (MARS) during
Impella support.
Overall survival was 73 %: 13 patients (58 %) experi-
enced recovery of heart function, 1 patient (5 %) was
bridged to LVAD implantation, 1 patient (5 %) underwent
heart transplantation, and 1 patient (5 %) was implanted a
BiVAD and was bridged to heart transplantation. Five pa-
tients (22 %) died, and 1 patient (5 %) met the criteria for
organ donation. Overall intensive care unit stay was 8 (4–
11) days, and hospital stay was 14 (8–30) days.
Hemodynamic and clinical data recorded at the 5 different
time points are shown in Table 4: notably, the improve-
ment of ejection fraction and mixed SVO2 during Impella
support were statistically significant (p = 0.042 and p =
0.022, respectively). No other parameter, including lac-
tates, improved significantly during Impella support.
Discussion
Despite significant improvements in coronary intervention
techniques, new frontiers in antithrombotic regimens and
significant advances in cardiac intensive care, mortality of
Table 1 Baseline data
Parameter Value
Male, n 20 (90)
Age, years 60 ± 13, 62 (52–68)
Height, cm, 172 ± 7, 175 (170–178)
Weight, kg 74 ± 11, 75 (70–84)
BSA 1.9 ± 0.1, 1.9 (1.8–2)
BMI 25 ± 3, 24.8 (22.9–26.2)
Comorbidity
Hypertension, n 6 (22)
Chronic renal failure, n 4 (18)
Dislipidemy, n 4 (18)
Overweight, n 3 (14)
Type II diabetes, n 1 (4.5)
Coronary artery disease, n 8 (36)
Idiopatic dilatative cardiomyopathy, n 2 (9)
Chronic obstructive pulmonary disease, n 3 (14)
Hypothyroidism, n 1 (4.5)
None, n 5 (22)
Cause of cardiogenic shock
Acute myocardial infarction, n 9 (41)
Postcardiotomic, n 5 (23)
Other, n 8 (36)
Data shown as number (percentage) or as mean ± standard deviation and
median (interquartile range)
BSA–Body surface area; BMI–Body mass index
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Table 2 Indication to IMPELLA , MCS-related management and outcomes
Patient ID Indication to implantation Rationale for impella’s
implantation
Devices implanted Hemolysis Anticoagulation Major bleeding Outcome
IMP1 CSMI (STEMI) Circulatory support, LV venting IMPELLA 2.5, IABP No UFH 25 U/ml (purge fluid) No LVAD




No UFH 25 U/ml (purge fluid) No Bridge to BIVAD and HTX




No IV bivalirudin No Organ donor (brain
death)
IMP4 Cardiogenic shock LV venting during ECMO IMPELLA 2.5, VA
ECMO
No IV bivalirudin No Recovery
IMP5 Postcardiotomic cardiogenic shock (Sleeve
procedure)
Coronary perfusion, LV venting IMPELLA 2.5, VA
ECMO, IABP
Yes IV bivalirudin Yes Bridge to HTX
IMP6 CSMI (STEMI) Coronary perfusion, circulatory
support
IMPELLA 2.5, IABP No IV bivalirudin No Recovery
IMP7 Cardiogenic shock following percutaneous
VT ablation
Circulatory support, LV venting IMPELLA 2.5 No IV bivalirudin No Recovery
IMP8 Cardiogenic shock (coronary ischemia) Circulatory support IMPELLA CP, IABP No UFH 50 U/ml (purge fluid) Yes Death (MOF-withdrawal
of care)
IMP9 CSMI (STEMI) Coronary perfusion, LV venting IMPELLA 2.5, VA
ECMO
No - No Death (MOF-withdrawal
of care)
IMP10 CSMI (STEMI) Coronary perfusion, circulatory
support, LV venting
IMPELLA 2.5, IABP No UFH 50 U/ml (purge fluid) No Recovery
IMP11 CSMI (STEMI) Coronary perfusion, circulatory
support
IMPELLA 2.5, IABP No UFH 50 U/ml (purge fluid) No Recovery
IMP12 Postcardiotomic cardiogenic shock (LV
aneurismectomy )
LV venting IMPELLA 2.5, VA
ECMO
Yes IV bivalirudin Yes Death (progressive
cardiogenic shock)
IMP13 Postcardiotomic cardiogenic shock (CABG) Coronary perfusion, circulatory
support
IMPELLA CP, IABP No UFH 50 U/ml (purge fluid) No Recovery
IMP14 CSMI (STEMI) Coronary perfusion, LV venting IMPELLA 2.5, VA
ECMO
Yes IV bivalirudin No Death (MOF-withdrawal
of care)






No IV bivalirudin No Recovery
IMP 16 CSMI (STEMI) Coronary perfusion, circulatory
support
IMPELLA 2.5, IABP No IV bivalirudin No Recovery
IMP 17 Cardiogenic shock (cronic myocarditis) Coronary perfusion, circulatory
support
IMPELLA 2.5, IABP Yes IV bivalirudin No Recovery
IMP18 Postcardiotomic cardiogenic shock (CABG) LV venting during VA ECMO IMPELLA 2.5, VA
ECMO, IABP
No UFH 25 U/ml (purge fluid) Yes Recovery
IMP 19 Cardiogenic shock (arrhytmia) Coronary perfusion, circulatory
support, severe AI












Table 2 Indication to IMPELLA , MCS-related management and outcomes (Continued)
IMP 20 Cardiogenic shock (coronary artery disease) Coronary perfusion, circulatory
support
IMPELLA CP No IV bivalirudin No Recovery
IMP 21 Cardiogenic shock (chronic heart failure,
multiple valvulopathy)
LV venting during VA ECMO IMPELLA 2.5, VA
ECMO, IABP




IMP 22 CSMI (STEMI) Coronary perfusion, circulatory
support, moderate AI
IMPELLA CP Yes UFH 25 U/ml (purge fluid) No Recovery
CSMI – cardiogenic shock myocardial infarction; STEMI – ST elevation myocardial infarction; VT – ventricular tachycardia; LV – left ventricle; VA ECMO – venoarterial extracorporeal membrane oxygenation; IABP –
intraortic balloon pump; IV – intravenous; UFH – unfractionated heparin; VAD–ventricular assit device;












cardiogenic shock remains unacceptably high (over 40
%) [8–10].
Our study reports an improved short-term survival
and a low rate of complications with the use of Impella
2.5/CP in the setting of cardiogenic shock of various eti-
ologies. The purpose of our study was to evaluate the
application of the percutaneous Impella device 2.5 and
CP either as the sole form of support or as part of a
combined MCS strategy with either IABP or VA ECMO
in the setting of cardiogenic shock of different etiologies
(CSMI, postcardiotomic cardiogenic shock, myocarditis
and cardiogenic shock of other etiologies) in a popula-
tion of 22 patients treated in our intensive care unit over
a 1-year period.
In our study the availability of a percutaneous LV assist
device has proved to be a valuable tool as adjunct to
other MCS devices. Indeed, the Impella pump can be
used as LV support device alone or in combination with
IABP and VA ECMO. In our case series, the main indi-
cation (i.e. in the Impella alone group) was in the pres-
ence of moderate signs of poor anterograde flow
combined with severe pulmonary congestion. The latter
shows the beneficial effects of active LV venting in the
“stone heart” with or without aortic regurgitation during
VA ECMO.
VA-ECMO increases LV afterload secondary to retro-
grade blood flow. In a severely dysfunctional heart with
a normal aortic valve, the increased afterload prevents
aortic valve opening, leading to LV volume overload and
increased wall stress, and therefore to pulmonary venous
congestion, pulmonary vascular injury and stasis with
thrombus formation within the LV cavity [11, 12].
Effective LV venting (as confirmed by clearing of lung
fields and reduction in LV dimensions) is crucial. Boulate
et al. [13] showed that about a third of patients undergo-
ing VA-ECLS bridge to LVAD suffer post-implant acute
lung injury (ALI), which carries a high mortality rate at 60
days follow up (87 %) and that one of the main risk factors
for ALI is the presence of pulmonary edema (i.e. incom-
plete LV unloading) while under ECLS preceding LVAD
implantation. Current management of LV distension dur-
ing VA ECMO includes IABP, percutaneous atrial septost-
omy with a catheter placed into the left atrium, and
central ECMO cannulation with direct placement of the
inflow cannulae in the left atrium or LV. However, such
Table 4 Hemodynamic and clinical data at the different time points: baseline, 30 min after Impella implantation, 24 h after
implantation, before weaning, 24 h after weaning
Parameter Baseline 30 min 24 h Before Weaning 24 h after weaning P
Inotropic score, n 5 (0–20) 10 (5–20) 5 (0–6) 0 (0–4) 0 (0–4) 0.1
Ejection fraction , % 20 (11.2–25) 15 (10–45) 20 (12–29) 32 (25–45) 32 (25–45) 0.042
LV-EDD, mm 55 ± 14.9 51 ± 13.6 51 ± 7.6 49 ± 11.2 59 ± 11.2 0.7
Cardiac Index, L/min/m2 1.8 (1.3–2.6) 2.5 (1.8–3.3) 2.3 (1.8–2.6) 2.6 (2.2–2.8) 2.6 (2.2–2.8) 0.7
Systolic pressure, mmHg 114 ± 29.9 115 ± 25.9 118 ± 17.6 112 ± 25.3 112 ± 25 0.8
Mean arterial pressure, mmHg 79 ± 11.1 82 ± 12.6 77 ± 13.3 78 ± 16.4 78 ± 16.4 0.3
Wedge Pressure, mmHg 15 ± 4.2 16 ± 2.5 13 ± 4.2 14 ± 3 14 ± 3.0 0.3
Lactates, mmol/L 1.5 (1.4–11) 5.7 (2.2–7.6) 2.3 (1.6–7.4) 1 (1.0–1.7) 1.1 (1.0–1.7) 0.5
Pro-BNP, pg/ml 15102 (7847–222422) - 12541 (1812–20344) 6488 (3319–18829) 6488 (3319–18829) 0.1
Mixed SVO2, % 58 ± 9.6 65 ± 12.5 62 ± 11.6 69 ± 2.5 69 ± 2.5 0.022
Data shown as number (percentage) or as median (interquartile range)
LV-EDD – Left ventricular end diastolic diameter; BNP – Brain natriuretic peptide
Table 3 Outcome data
Parameter Value
Impella support duration , hours 107 (54–141), 105 ± 58
Mechanical ventilation, hours 48 (14–92), 92 ± 153
Intensive care unit stay, days 8 (4–11), 13 ± 17
Hospital stay, days 14 (8–30), 18 ± 17
Serum troponin peak, ng/ml 8002 (1111–17613), 15953 ± 26189
Hemolysis, n 6 (27)
Major bleeding, n 4 (18)
Thromboembolic complications, n 0 (0)
Vascular complications, n 0 (0)
Arrhythmia, n 1 (5)
Lesions of cardiac structure, n 0 (0)
Survival, n 16 (73)
Outcomes
Recovery, n 13 (58)
LVAD implantation, n 1 (5)
HTX, n 2 (9)
Organ donation, n 1 (5)
Death, n 5 (23)
Data shown as number (percentage) or as median (interquartile range)
and mean ± standard deviation
LVAD – Left ventricular assist device; HTX – Heart transplantation
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LV venting techniques have not been systematically vali-
dated and results of our series are strikingly impressive.
A peripheral VA ECMO configuration was adopted in
the vast majority of patients (19 cases), as it is more
versatile, can be performed at bedside, and is applicable
to different clinical scenarios. On the contrary central
VA ECMO must be inserted in the operating theatre by
a cardiac surgeon, and was performed in only 3 patients
suffering from postcardiotomic cardiogenic shock . No
switching from peripheral to central VA ECMO cannula-
tion was performed.
The strategy of direct venting the LV chamber in post-
cardiotomic patients instead of using Impella is attract-
ive. However, Impella was inserted in the operating
room at the end of surgery only in 2 postcardiotomic pa-
tients of our study population, while in the other 3 cases
the Impella device was implanted in the ICU within the
first 12 postoperative hours, in the presence of signs of
inadequate LV unloading and stasis in the left ventricle.
Surgical venting is successful but can be positioned only
in the operating room. On the contrary, the Impella
pump can be inserted even after surgery in the ICU. For
this reason, the availabilty of a percutaneous device for
LV unloading is of fundamental importance also in pa-
tients with central VA ECMO. For the same reason,
before the availability of Impella at our Institution, IABP
was the most applied method to unload the LV, with
surgical venting being performed only in a few cases.
Furthermore, support with the Impella pump can be
started as an adjunct to aortic counterpulsation in pa-
tients failing on IABP or in patients with profound
cardiogenic shock and severe LV overload as observed
in the AMI-related CS cohort. In our study, most pa-
tients experienced either myocardial recovery (58 %)
or were bridged to LVAD or to heart transplantation
(14 %). Mortality rate was 23 %. One patient (5 %) met
the criteria for organ donation. Eligibility for organ
donation was considered as the result of satisfactory
organ perfusion and therefore efficacy of the MCS
combination applied (VA ECMO and Impella 2.5).
Brain death was explained as the consequence of a
prolonged no flow or low flow phase that preceded
ALS arrival and MCS implantation.
Moreover, we describe a low complication rate. This
observation is mainly the result of a low incidence of
major bleeding events: 2 cases of gastrointestinal bleed-
ing and 2 cases of cardiac tamponade after cardiac sur-
gery. However, it must be stressed that no patient who
received isolated Impella support experienced bleeding.
In addition, such events were observed either in patients
who received the VA ECMO-Impella combination after
cardiac surgery and therefore were managed with high
dose systemic anticoagulation or in patients who re-
ceived VA ECMO and combined Impella placement in
the setting of late referral cardiogenic shock after multi-
organ failure (MOF), including liver failure, had ensued.
No vascular complications were observed at the femoral
access site. Both the Impella 2.5 (Introducer size 13 Fr)
and CP (Introducer size 14 Fr) were removed safely by
manual compression. Impella was inserted at the pa-
tient’s bedside in six cases (27 %) under transesopha-
geal (TEE) guidance. Such data is of uttermost
importance and has extraordinary potential clinical
implications. Indeed, timing seems to be a key factor
in improving the survival of patients with CS. The
duration of the low output phase is indeed the main
determinant of multiple organ failure which might be-
come irreversible even after the initial cause of shock
has been treated and tissue perfusion restored. In this
context, the feasibility of TE echocardiography-guided
Impella placement is not only beneficial in terms of
restoration of adequate perfusion and LV venting, but
also reduces implantation time. Moreover, it over-
comes the need to transfer a critical patient on extra-
corporeal support to the cath lab for device insertion
under fluoroscopic guidance.
This study has some limitations. Firstly, the study popu-
lation is small and there is no control group. Nonetheless,
we consider our results impressive, as we describe a sur-
vival rate (73 %), that had never been reported in literature
in this patient population. Furthermore, this survival rate
does not include the patient (1 case, 5 % of the popula-
tion) who was considered eligible for organ donation as a
consequence of satisfactory organ perfusion as achieved
through MCS implantation. Secondly, indication for MCS
support was established at the discretion of the attending
physician. Furthermore, the non-randomized design of the
study does not allow to establish clear indications on the
application of this therapeutic strategy and further studies
are needed for this purpose.
Conclusions
Our preliminary data suggest that the best strategy to in-
crease the survival of cardiogenic shock in the present
era can not be relied upon a “one size fits all” strat-
egy and we have shown that systematic application
of LV venting with Impella pump strikingly increases
the survival rate of cardiogenic shock patients. The
feasibility of TE echocardiography-guided Impella
placement at the ICU bedside might further expand
the application of this strategy. Despite the highly
invasive nature of the CS management, patients ex-
perienced very few complications.
Mortality of cardiogenic shock has not improved over
the last decades, despite the systematic use of different
circulatory support devices. The design of previous stud-
ies has consistently focused on the comparison of one
device versus another or versus medical treatment. Even
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if not physiopathologically sound, this approach is effect-
ive and needs further studies.
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